Koss Olinger Consulting LLC Has $600,000 Stake in CRISPR Therapeutics AG $CRSP

Koss Olinger Consulting LLC decreased its position in CRISPR Therapeutics AG (NASDAQ:CRSP) by 72.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,447 shares of the company’s stock after selling 30,750 shares during the period. Koss Olinger Consulting LLC’s holdings in CRISPR Therapeutics were worth $600,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Capital International Investors raised its holdings in shares of CRISPR Therapeutics by 1.0% during the third quarter. Capital International Investors now owns 5,649,258 shares of the company’s stock valued at $366,128,000 after purchasing an additional 55,511 shares during the period. State Street Corp raised its holdings in shares of CRISPR Therapeutics by 35.6% during the second quarter. State Street Corp now owns 3,270,596 shares of the company’s stock valued at $159,082,000 after purchasing an additional 859,334 shares during the period. Orbis Allan Gray Ltd raised its holdings in shares of CRISPR Therapeutics by 76.9% during the second quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock valued at $134,467,000 after purchasing an additional 1,201,600 shares during the period. UBS Group AG raised its holdings in shares of CRISPR Therapeutics by 7.7% during the fourth quarter. UBS Group AG now owns 2,524,144 shares of the company’s stock valued at $132,366,000 after purchasing an additional 180,580 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of CRISPR Therapeutics by 2.9% during the third quarter. Vanguard Group Inc. now owns 2,364,645 shares of the company’s stock valued at $153,253,000 after purchasing an additional 66,556 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Trading Down 0.5%

Shares of CRSP stock opened at $56.10 on Friday. CRISPR Therapeutics AG has a 52-week low of $35.38 and a 52-week high of $78.48. The company has a debt-to-equity ratio of 0.32, a quick ratio of 17.96 and a current ratio of 17.97. The company has a 50-day simple moving average of $51.36 and a two-hundred day simple moving average of $53.13. The company has a market capitalization of $5.41 billion, a price-to-earnings ratio of -9.02 and a beta of 1.74.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%.The firm had revenue of $1.46 million during the quarter. Research analysts anticipate that CRISPR Therapeutics AG will post -4.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Needham & Company LLC upped their price objective on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a report on Friday, February 13th. Chardan Capital boosted their target price on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a research report on Saturday, February 14th. Piper Sandler reiterated an “overweight” rating and issued a $110.00 target price (up from $105.00) on shares of CRISPR Therapeutics in a research note on Tuesday, March 17th. Truist Financial upgraded shares of CRISPR Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Morgan Stanley reiterated an “underweight” rating and issued a $33.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $65.47.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 3,182 shares of the business’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $46.78, for a total value of $148,853.96. Following the transaction, the general counsel directly owned 94,308 shares in the company, valued at $4,411,728.24. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Samarth Kulkarni sold 10,020 shares of the business’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $46.78, for a total transaction of $468,735.60. Following the completion of the transaction, the chief executive officer owned 255,501 shares in the company, valued at approximately $11,952,336.78. The trade was a 3.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 42,749 shares of company stock valued at $2,100,723. Corporate insiders own 4.30% of the company’s stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent ?-thalassemia in collaboration with Vertex Pharmaceuticals.